Strategies for Fostering HPV Vaccine Acceptance

Gonik, Bernard

doi:10.1155/idog/2006/36797

Cited by 27 publications

(21 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the protectiveness of HPV vaccine has been demonstrated clearly, studies have shown that the general population has limited knowledge about this subject. In many studies, it has been shown that the community does not have much information about HPV vaccine (22)(23)(24)(25)(26). In our study, the rate of having heard of the vaccine was 11.7% in the group who had knowledge about the vaccine, while this rate reduced to 2.6% when all subjects were considered.…”

Section: Discussioncontrasting

confidence: 56%

Knowledge levels of adolescent girls about human papilloma virus and its vaccine

Cetin¹,

Verit²,

Keskın³

et al. 2014

Turk Arch Ped

View full text Add to dashboard Cite

Aim: The aim of our study was to evaluate the level of knowledge of the adolescent girls who presented to our clinic about human papilloma virus (HPV) infection and HPV vaccine. Material and Methods:Five hundred and one adolescent girls aged between 13 and 18 years who presented to the gynecology outpatient clinic between March 2012 and March 2013 were asked to answer the questions of the questionnaire about HPV and HPV vaccine. The "Participant Information Form" and "HPV Information Assessment Form" were used by examination of the related literature by the investigators. The data obtained were entered into the computer using the SPSS 16.5 program and evaluated. Descriptive statistics were shown with mean, standard deviation, number and percentage values. Results:The mean age of 501 subjects who were included into the study was 15.92 years. 390 subjects (77.8%) who were included in the study had no information about HPV. 111 subjects (22.2%) stated that they heard of HPV before or had information about HPV. The mean age of the subjects who had information about human papilloma virus was found to be 16.52 years. The mean age of 390 subjects (77.8%) who had no information about human papilloma virus was 15.75 years. It was found that only one of the subjects (0.9%) was vaccinated with HPV vaccine. When the subjects who did not wish to be vaccinated were asked for the reason, 40.9% stated that the reason was inadequate information, 26.4% stated that the reason was high cost, 16.4% stated that the reason was the fact that they did not consider themselves at risk and 16.4% stated that the reason was the fact that they were afraid of side effects. Conclusions:In our study, it was found that the adolescent girls who constituted our study group had insufficient information about HPV and HPV vaccine. Verbal, written and visual communication tools and internet should be used intensively and efficiently for the objective of introducing HPV vaccine and teaching the precautions related with prevention of cervix cancer in terms of public health. Primarily pediatrician and gynecologists and family physicians who give service for the adolescence age group should be supported to develop appropriate attitudes and behaviors related with HPV vaccine and infection. (Türk Ped Arş 2014; 49: 142-7)

show abstract

Section: Discussioncontrasting

confidence: 56%

Knowledge levels of adolescent girls about human papilloma virus and its vaccine

Cetin¹,

Verit²,

Keskın³

et al. 2014

Turk Arch Ped

View full text Add to dashboard Cite

show abstract

“…Data regarding dengue vaccine acceptance is very limited. However, several studies had reported vaccine acceptance in the context of other diseases (17)(18)(19)(20) and they were very helpful for immunization programs. We reviewed several factors associated with dengue vaccine acceptance.…”

Section: Factors Associated With Dengue Vaccine Acceptancementioning

confidence: 99%

Socioeconomic and Attitudinal Variables Associated with Acceptance and Willingness to Pay Towards Dengue Vaccine: A Systematic Review

Fajar

Harapan

2017

Arch Clin Infect Dis

View full text Add to dashboard Cite

Background: Currently, a dengue vaccine has been approved in some countries. The problem with this new vaccine is whether the public could accept and be willing to purchase. Objectives: This study aimed to provide solid data regarding factors associated with acceptance and willingness to pay for dengue vaccine. Methods: A systematic review with a meta-analysis was conducted on September-October 2016 for previous studies. Literatures from PubMed and Embase were searched for eligible publications (cut-off date for updates: September 10, 2016). The combined odds ratios (ORs) and 95% confidence intervals (95% CIs) were assessed using random or fixed effect model. Narrative review was used to analyze the data when they were not qualified for meta-analysis. Results: There were several factors associated with acceptance of dengue vaccine including attitude toward vaccination, preventive measures against dengue, attitude towards dengue, knowledge on dengue, socioeconomic level, and dengue experience. However, our meta-analysis revealed that only attitude towards vaccination (OR95%CI = 0.313 [0.137 -0.713], P = 0.006) and socioeconomic level (OR95%CI = 0.576 [0.385 -0.862], P = 0.007) had significant associations with dengue vaccine acceptance. Studies also revealed that preventive measures against dengue, attitude towards dengue, knowledge on dengue fever, knowledge on dengue viruses, socioeconomic levels, dengue experience, and vaccine price were associated with willingness to pay. However, none of those data was qualified for meta-analysis. Conclusions: Meta-analysis reveals that good attitude towards vaccination and higher socioeconomic levels are associated with better acceptance of dengue vaccine.

show abstract

“…57,60,61 Lack of assurance from a trusted source that the vaccine is safe and effective and has minimal side effects hinders development of a positive perception of the vaccine.…”

Section: Creating Widespread Demandmentioning

confidence: 99%

Moving Forward: Human Papillomavirus Vaccination and the Prevention of Cervical Cancer

Vetter

Geller²

2007

Journal of Women's Health

View full text Add to dashboard Cite

In June 2006, the Food and Drug Administration (FDA) approved the first human papillomavirus (HPV) vaccine. The vaccine was subsequently recommended by the Centers for Disease Control and Prevention's (CDC) Advisory Committee for Immunization Practices (ACIP) for routine vaccination of 11-12-year-old girls and catch-up vaccination of females 13-26 years of age. With the approval of the first HPV vaccine, cervical cancer now has a primary prevention tool. However, the availability of an HPV vaccine will not change the course of cervical cancer in this country unless there is both widespread demand by and access for the targeted populations. Demand will require recognition of the need for protection against HPV infection as well as a positive perception of the vaccine as safe and efficacious. General knowledge of HPV and its relationship to cervical cancer is limited; some parents and healthcare providers are hesitant to vaccinate preadolescent girls. Access to the expensive vaccine will not be increased without addressing financial constraints. Although the Vaccines for Children (VFC) program has added HPV to its vaccine plan, not all private insurers have approved coverage, and the uninsured and underinsured may have limited access. Moving forward will require a well-planned and executed public information campaign by trusted sources and the development of a comprehensive vaccine administration program. Although mandates would assure the broadest coverage, controversies surrounding mandates may deter work toward broad coverage. States should focus on developing a comprehensive program and then return to the mandate issue if coverage does not meet public health objectives.

show abstract

Strategies for Fostering HPV Vaccine Acceptance

Cited by 27 publications

References 29 publications

Knowledge levels of adolescent girls about human papilloma virus and its vaccine

Knowledge levels of adolescent girls about human papilloma virus and its vaccine

Socioeconomic and Attitudinal Variables Associated with Acceptance and Willingness to Pay Towards Dengue Vaccine: A Systematic Review

Moving Forward: Human Papillomavirus Vaccination and the Prevention of Cervical Cancer

Contact Info

Product

Resources

About